m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT00540
|
[1], [2], [3] | |||
.png)
.png)
 : modification sites
Indirect
Enhancement
m6A modification
FSCN1
FSCN1
METTL3
Methylation
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Fascin (FSCN1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | RNA modification (RNAMod) >> Adenosine-to-Inosine editing (A-to-I) | ||||
| Epigenetic Regulator | Interferon-inducible protein 4 (ADAR1) | WRITER | View Details | ||
| Regulated Target | MicroRNA 200b (MIR200B) | View Details | |||
| Crosstalk Relationship | A-to-I → m6A | Enhancement | |||
| Crosstalk Mechanism | RNA modification indirectly impacts m6A modification through downstream signaling pathways | ||||
| Crosstalk Summary | ADAR1 interacts with MicroRNA 200b (MIR200B), increasing it's A-to-I level and promoting its physical interaction with Fascin (FSCN1), which was regulated by METTL3-mediated m6A modification. | ||||
In-vitro Model |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
| CAL-62 | Thyroid gland anaplastic carcinoma | Homo sapiens | CVCL_1112 | ||
| TPC-1 | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Fascin (FSCN1) | 1 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
 Compound Name |
NP-G2-044 | Phase 1 | [4] | |
|---|---|---|---|---|
| Synonyms |
1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| External Link | ||||
References